Linical Taiwan Co., Ltd.

     President & CEO: Vivian SF LEE
     Founded Date: 2013/05/13
     Tel: 886-2-2503-8090
     Address: Room E, 5F, No. 2, Sec. 3, Minsheng E. Rd., Taipei 104, Taiwan



Company Profile:

Linical Co., Ltd (‘Linical’) is a premier global CRO headquartered in Osaka, Japan, listed in the prime segment of the Tokyo Stock exchange, and dedicated to serve its client as a true partner in development. In April 2018, Linical acquired a US-based global CRO i.e. Accelovance Inc., to offer broad scope of services to clients. With more than 1000 employees Linical directly covers a total of 26 countries in Asia-Pacific including Japan, Europe and N. America via its own offices and entities, as follows:
Austria, Belgium, Bosnia Herzegovina, Croatia, France, Germany, Hungary, Italy, Japan, Netherlands, Portugal, Russia, Serbia, Montenegro, Slovenia, Spain, China, South Korea, Singapore, Switzerland, Taiwan, Ukraine, The United Kingdom, Canada, The United States of America.

• Linical has strong track records in all phases with particular focus on oncology, central nervous system (CNS) and immunology drug development, covering early as well as late development phases, from First-in-Man and Proof-of-Concept studies to Phase 2/3 and global post-marketing trials, and almost 20 years of oncology, CNS and immunology drug development expertise. Our project approach and processes are tailored to the specific needs of oncological, CNS and immunology trials. Linical has 4 in-house oncologists, a corporate pharmacovigilance unit, and a dedicated team of oncology, CNS and immunology-trained project managers and monitoring staff.

• Linical’s Corporate Clinical Data Management, Biostatistics and e-Trial Solutions team is based in Madrid, Spain, with an additional team located in Seoul, Korea. Our Data Science Center offers tailored concepts across all key therapeutic areas with particular expertise not only in pivotal Phase 2/3 trials, but also in late-phase approaches such as observational studies, PAS and PASS, to serve global as well as regional and national projects.

• In Japan, the Department of IDDB (Innovative Drug Development Business) also offers consultations service in market analysis, regulatory support and medical writing including application and meeting with PMDA, and partnering support for Japanese market.

We offer individualized solutions that are tailored to the specific needs of our clients. We work as integrated teams functioning with maximum transparency throughout each study, making sure that the sponsor is kept up to date on all study parameters and progress.

A dedicated clinical development team with deep industry and therapeutic area expertise across all phases, we deliver the spirit of our team in line with the truly clinical development partner to establish Linical Taiwan as the reliable and competent business partner with major bio/pharmaceutical companies in clinical development. Through strong knowledge to connect between IND and NDA, we drive predictable and effective delivery for clinical commercial and real-world value.

Our Mission
To become a think tank specializing in clinical trials (the CRO that provides know-how).

Management Philosophy
We pursue happiness of patients, business partners, shareholders and employees which are our stakeholders. For that purpose, we strive to offer high-quality service as professionals in all situations of new drug development.